How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

801 results for

Valproic Acid Toxicity

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Molecular Signature of Valproic Acid in Breast Cancer With Functional Imaging Assessment

white blood cell histone acetylation. Published in vitro studies have shown sensitivity of breast cancer cells to histone deacetylase inhibitors (Fortunati et al., 2008; Fuino et al., 2003; Hodges-Gallagher et al., 2007; Olsen et al., 2004). The investigators' gene array data predict sensitivity to valproic acid in over half of breast cancers [Bild, unpublished]. The investigators hypothesize that in women with newly diagnosed breast cancers valproic acid will have an unacceptable toxicity rate less (...) intrinsic breast subtype by the Breast Bioclassifier correlates with changes in tumor proliferation rate or changes in DCE-MRI markers of size and vascularity following treatment with valproic acid. [ Time Frame: December, 2013 ] Determine if women have dose-limiting toxicities for valproic acid over 7-12 days [ Time Frame: December, 2013 ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your

2009 Clinical Trials

82. Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome

Identifier: NCT00977132 Recruitment Status : Terminated (delayed recruitment) First Posted : September 15, 2009 Last Update Posted : March 18, 2015 Sponsor: Heinrich-Heine University, Duesseldorf Information provided by (Responsible Party): Heinrich-Heine University, Duesseldorf Study Details Study Description Go to Brief Summary: As part of a palliative therapy concept, feasibility, toxicity, and effectiveness of treatment with the combination of Valproic acid and lenalidomide in Myelodysplastic (...) Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study

2009 Clinical Trials

83. Use of Hydralzaine and Valproic Acid in Advanced Solid Tumor Malignancies

Party): New Mexico Cancer Care Alliance Study Details Study Description Go to Brief Summary: Primary Objective: The primary endpoint to this study will be to document the toxicities, and reversibility of toxicities, of this regimen of hydralazine and valproic acid in patients with advanced, unresectable, previously treated lung cancers, for whom no acceptable standard therapy is available. A primary endpoint will be to determine any potential dose limiting toxicities, and the Maximal Tolerated Dose (...) state level of valproic acid in the blood. Hydralazine is administered at 400 mg/day in this cohort as 100 mg four times per day. Other Names: Apresoline (Hydralazine) Depakote (Valproic Acid) Outcome Measures Go to Primary Outcome Measures : A primary endpoint will be to determine any potential dose limiting toxicities, & the Maximal Tolerated Dose of hydralazine & valproic acid regimen. [ Time Frame: 28 days ] Secondary Outcome Measures : To determine any potential anti-tumor effects

2009 Clinical Trials

84. Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine

Information provided by (Responsible Party): Øystein Bruserud, University of Bergen Study Details Study Description Go to Brief Summary: Hypothesis: Combined treatment with valproic acid and ATRA can be used to achieve disease stabilization for a subset of patients with acute myelogenous leukemia (AML), and this effect can be improved without serious toxicity by adding low-dose cytarabine to this treatment. Adult patients >18 years of age who can be included: Elderly patients who cannot achieve standard (...) : Acute myelogenous leukemia all-trans retinoic acid valproic acid cytarabine Disease stabilization survival toxicity Additional relevant MeSH terms: Layout table for MeSH terms Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Neoplasms by Histologic Type Neoplasms Cytarabine Tretinoin Valproic Acid Histone Deacetylase Inhibitors Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Antiviral Agents Anti-Infective Agents

2009 Clinical Trials

85. Single valproic acid treatment inhibits glycogen and RNA ribose turnover while disrupting glucose-derived cholesterol synthesis in liver as revealed by the [U-13C6]-d-glucose tracer in mice (PubMed)

Single valproic acid treatment inhibits glycogen and RNA ribose turnover while disrupting glucose-derived cholesterol synthesis in liver as revealed by the [U-13C6]-d-glucose tracer in mice Previous genetic and proteomic studies identified altered activity of various enzymes such as those of fatty acid metabolism and glycogen synthesis after a single toxic dose of valproic acid (VPA) in rats. In this study, we demonstrate the effect of VPA on metabolite synthesis flux rates and the possible use (...) of abnormal (13)C labeled glucose-derived metabolites in plasma or urine as early markers of toxicity. Female CD-1 mice were injected subcutaneously with saline or 600 mg/kg) VPA. Twelve hours later, the mice were injected with an intraperitoneal load of 1 g/kg [U-(13)C]-d-glucose. (13)C isotopomers of glycogen glucose and RNA ribose in liver, kidney and brain tissue, as well as glucose disposal via cholesterol and glucose in the plasma and urine were determined. The levels of all of the positional (13)C

Full Text available with Trip Pro

2009 Metabolomics

86. Compensate victims!

the manufacturers to court, to gain media coverage, and to get politicians' attention. In France, the brand names Mediator° (benfluorex) and Depakine° (valproic acid) are associated with two notorious public health disasters that generated numerous legal proceedings, intense media coverage, and indignant political reactions. The victims of these two very different scandals were recognised as such because they were able to get media coverage and thus capture politicians' attention. They were subsequently (...) the individuals concerned a considerable amount of money and mental energy. Fewer in number, but no less noteworthy, are the victims of severe drug reactions such as toxic epidermal necrolysis. Why not simply recognise, once and for all, that every year thousands of patients are victims of drug toxicity and set up a collective fund for compensating all such individuals? The fund would be paid for by drug companies or their insurers. The first step is to recognise that accidents due to medicinal drugs

2017 Prescrire

87. Palliative Care for the Patient with Incurable Cancer or Advanced Disease: Part 2: Pain and Symptom Management

cases. • See Palliative Care Part 2: Pain and Symptom Management – Constipation. Nausea • Resolves after ~ 1 week. Consider metoclopramide * first line; avoid dimenhydrinat e (Gravol®). Sedation • Stimulants may be helpful if sedation persists, e.g., methylphenidate, dextroamphetamine, or modafanil. Myoclonus • May respond to benzodiazepines, but may be a sign of opioid toxicity requiring hydration, opioid dose reduction or rotation. Delirium • Assess for other causes, e.g., hypercalcemia, UTI

2017 Clinical Practice Guidelines and Protocols in British Columbia

88. CRACKCast E162 – Opioids

, guanfacine, valproic acid, gamma-hydroxybutyrate (GHB), ethanol, sedative hypnotics, and atypical antipsychotics. Nontox: pontine stroke or hemorrhage, hypoglycemia. 2) What opioids don’t cause miosis? Meperidine (Demerol) causes mydriasis. 3) Risk factors for opioid overdose? Using alone. IVDU. Co-ingestions. Using shortly after detox. Any drugs acquired on the street. Fentanyl use. 4) What is NAPE? Narcan induced pulmonary edema. Similar to negative-pressure associated pulmonary edema – while patient (...) , miosis, and most importantly, respiratory depression – but presentations may be variable. A negative urine screen is unreliable, and absence of detection should not deter a diagnosis of opioid intoxication when clinical findings support it. Airway protection, oxygenation, ventilation, and early administration of naloxone are the cornerstones for management of patients with opioid toxicity. The duration of action of many opioids, especially after overdose, is significantly longer than that of naloxone

2018 CandiEM

89. CRACKCast Episode 148 – Acetaminophen

testing Give the antidote = NAC when appropriate. Its all about the nomogram! Don’t forget about the differential diagnosis! In patients with elevated Liver enzymes / abnormal liver function and with or without Renal failure, think: acute tubular necrosis Rhabdomyolysis ischemic hepatitis alcoholic hepatic disease cyclopeptide-containing mushroom toxicity (eg Amanita Phalloides) viral hepatitis Wilson disease, other hepatic toxicities (eg, valproic acid, isoniazid [INH], statins, herbal medications (...) that doesn’t have a bottle or two around. The issue is its relatively a silent clinical syndrome until overt hepatocellular toxicity has ensued! NAC saves lives! Increased glutathione availability Direct binding of NAPQI Provision of inorganic sulfate Reduction of NAPQI back to paracetamol 18% of all unexplained liver failure ends up being attributed to APAP overdose As with all tox, don’t forget the basics (see episode 147) But with APAP overdoses there are 3 goals: Determine the patient’s risk Diagnostic

2018 CandiEM

90. CRACKCast E147 – General Approach to the Poisoned Patient

Emulsion Local Anesthetics, Systemic Toxicity, Fat Soluble Medications [4] List 10 T oxins T hat C ause D elirium Ten toxins that cause delirium (As per UptoDate) are as follows: Prescription medications (e.g., opioids, sedative-hypnotics, antipsychotics, etc…) Non-prescription medications (e.g., OTC antihistamines) Drugs of abuse (e.g., ethanol, heroin, hallucinogens, etc…) Withdrawal states (e.g., ethanol, benzodiazepines) Medication side effects (e.g., hyperammonemia from valproic acid, serotonin (...) ialyzable D rug P roperties Low molecular weight Low protein binding or easily saturable protein binding in a toxicological context Low volume of distribution Low plasma clearance Low dialysate drug concentrations High water solubility For more information, check out the following link: [11] List 8 D ialyzable D rugs Here’s the list: STUMBLED Salicylates Theophylline Uremia Metformin / methanol Barbituates Lithium Ethylene glycol Depakote – valproic acid Or IV STUMBLE ( add Isoniazid and Valproic Acid

2018 CandiEM

91. Treatment of cerebellar motor dysfunction and ataxia

ataxia type 2, 4-aminopyridine 15 mg/d probably reduces ataxia attack frequency over 3 months (1 Class I study). For patients with ataxia of mixed etiology, riluzole probably improves ataxia signs at 8 weeks (1 Class I study). For patients with Friedreich ataxia or spinocerebellar ataxia (SCA), riluzole probably improves ataxia signs at 12 months (1 Class I study). For patients with SCA type 3, valproic acid 1,200 mg/d possibly improves ataxia at 12 weeks. For patients with spinocerebellar (...) direct current stimulation ; TMS = transcranial magnetic stimulation ; TRH = thyrotropin-releasing hormone ; VPA = valproic acid The cerebellum is composed of the vermis, the hemispheres, and 3 cerebellar peduncles on each side, and contributes largely to balance and motor coordination. The causes of cerebellar dysfunction are numerous and include vitamin deficiencies, structural lesions (caused by tumors or trauma), infection, inflammation, toxins, neurodegeneration, genetics, stroke, multiple

2018 American Academy of Neurology

92. Practice Guideline Update Summary: Efficacy and Tolerability of the New Antiepileptic Drugs I: Treatment of New-onset Epilepsy

epilepsy or generalized-onset GTC seizures (1 Class II study), no recommendations can be made regarding TPM use at the studied doses, particularly in new-onset epilepsy and pediatric patients.AAN.com ©2018 American Academy of Neurology Monotherapy in adults and children with new-onset GE or unclassified GTC seizures Level Recommendation No Recommendation Evidence is insufficient to compare efficacy of LTG and TPM with that of valproic acid (VPA) in children and adults with new-onset or relapsing GE (1 (...) Recommendation Level B LTG use should be considered to decrease seizure frequency. Levels B and Level C LTG use should be considered (Level B) and GBP use may be considered (Level C) to decrease seizure frequency in patients aged =60 years. Level C LEV use may be considered to decrease seizure frequency. Level C ZNS use may be considered to decrease seizure frequency. Level C VGB use appears to be less efficacious than immediate-release carbamazepine (CBZ) use and may not be offered; furthermore, toxicity

2018 American Academy of Neurology

93. Evaluation and Treatment of Hirsutism in Premenopausal Women

by a partner ( ), exogenous androgens or anabolic steroids ( ), or valproic acid when evaluating patients with hirsutism. 1.0 Diagnosis of Hirsutism 1.1. We suggest testing for elevated androgen levels in all women with an abnormal hirsutism score (2 |⊕⊕OO). In those cases where serum total testosterone levels are normal, if sexual hair growth is moderate/severe or sexual hair growth is mild but there is clinical evidence of a hyperandrogenic endocrine disorder (such as menstrual disturbance or progression (...) in athletes, users of dietary supplements, patients with sexual dysfunction, or in patients with a partner who uses testosterone gel) and valproic acid (a consideration in patient with neurologic disorders). An accurate and specific assay, such as mass spectrometry, is the best choice for assessing serum total testosterone concentrations. Norms are standardized for early morning, when levels are the highest, and for days 4 to 10 of the menstrual cycle (see Section 5, Androgen Testing Remarks) when ovarian

Full Text available with Trip Pro

2018 The Endocrine Society

94. Evaluation and Treatment of Hirsutism in Premenopausal Women

by a partner ( ), exogenous androgens or anabolic steroids ( ), or valproic acid when evaluating patients with hirsutism. 1.0 Diagnosis of Hirsutism 1.1. We suggest testing for elevated androgen levels in all women with an abnormal hirsutism score (2 |⊕⊕OO). In those cases where serum total testosterone levels are normal, if sexual hair growth is moderate/severe or sexual hair growth is mild but there is clinical evidence of a hyperandrogenic endocrine disorder (such as menstrual disturbance or progression (...) in athletes, users of dietary supplements, patients with sexual dysfunction, or in patients with a partner who uses testosterone gel) and valproic acid (a consideration in patient with neurologic disorders). An accurate and specific assay, such as mass spectrometry, is the best choice for assessing serum total testosterone concentrations. Norms are standardized for early morning, when levels are the highest, and for days 4 to 10 of the menstrual cycle (see Section 5, Androgen Testing Remarks) when ovarian

Full Text available with Trip Pro

2018 The Endocrine Society

95. Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU

randomized trial (R01HL132887) evaluating nutrition and exercise in acute respiratory failure and, related to this trial, is currently in receipt of an unrestricted research grant and donated amino acid product from Baxter Healthcare and an equipment loan from Reck Medical Devices to two of the participating study sites, external to his institution. Dr. Slooter has disclosed that he is involved in the development of an electroencephalogram-based delirium monitor, where any (future) profits from

2018 Society of Critical Care Medicine

96. CRACKCast E175 – Neurologic Disorders

) Second line: Fosphenytoin/phenytoin Dose: 20 mg/kg Interval: IV over 5-10 minutes (in NS or D5W) Phenobarbital Dose: 20 mg/kg Interval: 1 mg/kg/min over 20 minutes Valproic acid Note: probably has a role, but not as fully researched in kids How does it differ if you are unable to obtain IV or IO access? Remember: Effectiveness (compared to IV) in descending order: IN >>> Buccal >> PR IN route Midazolam Dose: 2 mg/kg (max 5 mg/nostril) IM route Midazolam Dose: 2 mg/kg Fosphenytoin Dose: 20 mg/kg IM (...) Overview Causes of altered mental status in children are broad. Use a comprehensive approach! (e.g. DIMES) Includes vascular events (e.g., stroke, arteriovenous malformation with bleed), infection (e.g., meningitis, sepsis, encephalitis), trauma, toxic ingestion, anatomic or structural abnormality (e.g., intracranial mass or tumor), metabolic derangements, intussusception, or seizures, which may be subclinical. Altered mental status in children has a varied spectrum of clinical presentations and may

2018 CandiEM

97. Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients

be experiencing toxicity from them. Tier III tests can also be examined when they are clin- ically indicated, either by history of use, medication list, or very high probability of misuse/abuse, in a specific patient rather than for every patient. Frequency of laboratory testing CONSENSUS-BASED EXPERT OPINION #1: Based on level II evidence, baseline drug testing should be performed prior to initiation of acute or chronic controlled substance therapy. In addition, random drug testing should be performed (...) be enzymatic or chemi- cal. Enzymes used include ß-glucuronidase from abalone, ß-glu- curonidase type H-3 from Helix pomatia, ß-glucuronidase type L-II from Patella vulgata, and glusulase(23, 24). Recombinant ß-glucuronidase is also now available (IMCSzyme from IMCS). A common approach to chemical hydrolysis includes incubation with concentrated hydrochloric acid. Hydrolysis conditions, such as substrate concentrations, temperature, pH, and time, should be evaluated and optimized by the laboratory. One

2018 American Academy of Pain Medicine

98. CRACKCast E103 – Headache Disorders

: Acetaminophen or NSAIDs First line agents for moderate-severe attacks: 1. DHE 2. Triptans 2.1. Sumatriptan 3. Prochlorperazine 4. Metoclopramide 5. Droperidol 6. Ketorolac Second line agents: 1. Morphine 1.1. Hydromorphone less effective 2. Magnesium 3. Valproic Acid More details: MILD TO MODERATE Acetaminophen 500–1000 mg PO Ibuprofen 600–800 mg PO Gastrointestinal upset Naproxen sodium 275–550 mg PO Gastrointestinal upset MODERATE TO SEVERE First-Line Agents: Dihydroergotamine (DHE) 1 mg IV or IM; may (...) IV or 30 to 60 mg IM Gastrointestinal upset; avoid this medication in elderly and in patients with renal insufficiency Second Line Agents: Morphine 4 to 8 mg IM or IV Opioids less efficacious than other treatment modalities Magnesium 2 g IV More efficacious in migraine with aura Valproic acid 1 g IV Contraindicated in pregnancy 5) List four migraine variants. Neuroimaging should be considered for older or immunocompromised patients with new-onset headaches, headaches associated with unexplained

2017 CandiEM

99. CRACKCast E102 – Seizures

Patient older than 65 years old Seizure duration more than 15 minutes [5] Describe the 1st, 2nd and third line management options for seizure See table 15.1 in 9 th Edition of Rosens – Seizure chapter In summary, they discuss abortive options for seizure, with dosing and precautions, particularly: Initial therapy of either: Diazepam Lorazepam Midazolam Second tier treatments of either: Phenytoin Fosphenytoin Valproic acid Levetiracetam Third-tier treatments Pentobarbital Phenobarbital Midazolam (...) epilepticus can mimic Hypoglycemia CNS infection CNS vascular event Drug toxicity Psychiatric disorder Metabolic encephalopathy Migraine Transient global amnesia [4] What factors predict abnormal CT findings in seizure patients? See Box 92.3 – Differential Diagnosis of AMS in Patient Who Has Seized Focal abnormality on neurological examination Malignancy Closed head injury Neurocutaneous disorder Focal onset of seizure Absence of a history of alcohol abuse History of cysticercosis Altered mental status

2017 CandiEM

100. CRACKCast E115 – Suicide

· Thyroid-stimulating hormone (TSH) (for suspected thyrotoxicosis or thyroid abnormality) Toxicologic Labs · Urine screen for drugs of abuse (to explain acutely altered mental status; to assist ongoing psychiatric care) · Ethanol level (to explain acutely altered mental status; to assist ongoing psychiatric care) · Testing for potential toxic ingestion (eg, aspirin, acetaminophen, serum osmolar gap) · Serum levels of measurable drugs (eg, lithium, valproic acid, phenytoin) Imaging · Electrocardiogram (...) diagnostic tests, which may be ordered based on your history and physical. Table 105.3 (9 th Edition) – Potential Targeted Diagnostic Testing in ED Patients Presenting with Suicidality General Labs · Pregnancy test (in females of childbearing age) · Complete blood count (for suspected anemia) · Serum chemistries (for suspected electrolyte abnormalities) · Urinalysis (for suspected infection) · Liver function tests (LFTs), ammonia (for suspected liver disease or valproic acid use) · Coagulation studies

2017 CandiEM

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>